Log in

NASDAQ:BPTHBio-Path Stock Price, Forecast & News

-0.07 (-1.46 %)
(As of 08/13/2020 04:00 PM ET)
Today's Range
Now: $4.74
50-Day Range
MA: $5.12
52-Week Range
Now: $4.74
Volume37,500 shs
Average Volume93,685 shs
Market Capitalization$17.50 million
P/E RatioN/A
Dividend YieldN/A
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Read More
Bio-Path logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BPTH



Sales & Book Value

Annual Sales$40,000.00
Book Value$7.31 per share


Net Income$-8,600,000.00


Market Cap$17.50 million
Next Earnings Date8/14/2020 (Confirmed)
OptionableNot Optionable
-0.07 (-1.46 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

How has Bio-Path's stock price been impacted by Coronavirus (COVID-19)?

Bio-Path's stock was trading at $4.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BPTH stock has decreased by 0.2% and is now trading at $4.74.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Bio-Path?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bio-Path

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Bio-Path

How were Bio-Path's earnings last quarter?

Bio-Path Holdings Inc (NASDAQ:BPTH) issued its earnings results on Friday, August, 14th. The company reported ($0.55) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.89) by $0.34.
View Bio-Path's earnings history

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path's stock reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for BPTH?

1 analysts have issued 1 year price objectives for Bio-Path's stock. Their forecasts range from $18.00 to $18.00. On average, they expect Bio-Path's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 279.7% from the stock's current price.
View analysts' price targets for Bio-Path

What are Wall Street analysts saying about Bio-Path stock?

Here are some recent quotes from research analysts about Bio-Path stock:
  • 1. According to Zacks Investment Research, "BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. " (7/20/2020)
  • 2. HC Wainwright analysts commented, "We believe quarterly operating expenses could approximate $2M in 2H19. The company had $17.1M in cash at the end of June 2019, which should support operations into 2H20. In the wake of this update, we reiterate our Buy rating and $28 price target. Combo trial of prexigebersen + decitabine could report safety data in 2H19. Prexigebersen is an antisense DNA molecule that blocks expression of growth factor receptor-bound protein 2 (Grb-2). Prexigebersen has shown favorable safety and positive Phase 2 interim data in combination with low-dose cytarabine (LDAC) in elderly patients with acute myeloid leukemia (AML), demonstrating 65% objective response with a 29% complete response (CR) rate." (8/16/2019)

Has Bio-Path been receiving favorable news coverage?

News headlines about BPTH stock have trended very negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bio-Path earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Bio-Path

Are investors shorting Bio-Path?

Bio-Path saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 15,300 shares, an increase of 62.8% from the June 15th total of 9,400 shares. Based on an average daily volume of 95,400 shares, the days-to-cover ratio is presently 0.2 days.
View Bio-Path's Short Interest

Who are some of Bio-Path's key competitors?

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), NVIDIA (NVDA), Energy Transfer LP Unit (ET), Amarin (AMRN), Canopy Growth (CGC), Micron Technology (MU), Palatin Technologies (PTN), Advanced Micro Devices (AMD) and Ford Motor (F).

Who are Bio-Path's key executives?

Bio-Path's management team includes the following people:
  • Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 70)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 63)
  • Mr. Anthony Price MBA, Director of Fin. and Accounting
  • Dr. Alan MacKenzie Ph.D., Consultant
  • Dr. Thomas A. Walker Ph.D., Consultant

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $4.74.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $17.50 million and generates $40,000.00 in revenue each year. The company earns $-8,600,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis. Bio-Path employs 8 workers across the globe.

What is Bio-Path's official website?

The official website for Bio-Path is www.biopathholdings.com.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.